13 results on '"Rammensee, Hans-Georg"'
Search Results
2. Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
- Author
-
Roerden, Malte, Märklin, Melanie, Salih, Helmut R., Bethge, Wolfgang A., Klein, Reinhild, Rammensee, Hans-Georg, Nelde, Annika, and Walz, Juliane S.
- Subjects
ACUTE myeloid leukemia ,TREATMENT effectiveness ,HLA histocompatibility antigens ,ANTIGEN presentation - Abstract
Low human leukocyte antigen (HLA)-DR expression might compromise CD4
+ T-cell-mediated anti-tumor immunity. Its immunological and clinical significance however remain undefined in non-promyelocytic acute myeloid leukemia (AML). Taking advantage of mass spectrometry-based immunopeptidome analysis of primary AML samples (n = 31), we studied the implications of low HLA-DR expression for antigen presentation and analyzed its association with disease characteristics and survival within a cohort of 399 AML patients. Remarkably, overall HLA-DR/DQ immunopeptidome diversity was preserved in AML with low HLA-DR expression (HLA-DRlow AML) and was associated with a shift in HLA-DR/DQ allotype abundances (HLA-DQ to HLA-DR/DQ ligand ratio 0.36 vs 0.19 in HLA-DRlow and HLA-DRhigh patients, respectively). Consistent with unimpaired antigenicity, survival was similar in HLA-DRlow and HLA-DRhigh patients. Demonstrating for the first time that overall HLA-DR/DQ antigen presentation is preserved in HLA-DRlow AML, our findings provide a rationale for the non-inferior outcome observed in HLA-DRlow AML patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
3. Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
- Author
-
Walz, Juliane Sarah, Kanz, Lothar, Nelde, Annika, Salih, Helmut Rainer, Kowalewski, Daniel Johannes, Backert, Linus, Rammensee, Hans-Georg, Stevanović, Stefan, Kohlbacher, Oliver, and Weide, Benjamin
- Subjects
CHRONIC lymphocytic leukemia ,T-cell lymphoma ,ANTIGEN receptors ,SKIN cancer ,IMMUNE response - Abstract
The course of chronic lymphocytic leukemia (CLL), inducing an immunosuppressed state that also affects T cells as central components of adaptive immunity, predisposes patients to develop second malignancies with skin cancer being the most common. Recently, we found that prevalence of memory T cells with specificity for CLL-associated antigens defined by mass spectrometry-based immunopeptidome analysis correlated with a significant survival benefit. Here, we analyzed our CLL patient cohort for second skin (pre)malignancies and found a significantly lower incidence of skin cancer in the patients showing immune responses to CLL-associated antigens. Surprisingly, CLL-associated antigen-specific immune responses did not associate with clinical characteristics including leukocyte, neutrophil, and thrombocyte count, hemoglobin, immunoglobulin levels, or CD8
+ and CD4+ T-cell immune status. Our data indicate that the CLL-specific immune signature of a given patient, defined by antigen-specific T-cell responses, might represent an independent marker to identify CLL patients susceptible for the development of skin malignancies. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
4. HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy.
- Author
-
Nelde, Annika, Kowalewski, Daniel J., Backert, Linus, Schuster, Heiko, Werner, Jan-Ole, Klein, Reinhild, Kohlbacher, Oliver, Kanz, Lothar, Salih, Helmut R., Rammensee, Hans-Georg, Stevanović, Stefan, and Walz, Juliane S.
- Subjects
CHRONIC lymphocytic leukemia treatment ,T cells ,IMMUNE response ,THERAPEUTICS - Abstract
Recent studies suggest that CLL is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell-based immunotherapy. However, CLL is associated with a profound immune defect, which might represent a critical limitation for mounting clinically effective antitumor immune responses. As several studies have demonstrated that lenalidomide can reinforce effector T-cell responses in CLL, the combination of T-cell-based immunotherapy with the immunomodulatory drug lenalidomide represents a promising approach to overcome the immunosuppressive state in CLL. Antigen-specific immunotherapy also requires the robust presentation of tumor-associated HLA-presented antigens on target cells. We thus performed a longitudinal study of the effect of lenalidomide on the HLA ligandome of primary CLL cells in vitro. We showed that lenalidomide exposure does not affect absolute HLA class I and II surface expression levels on primary CLL cells. Importantly, semi-quantitative mass spectrometric analyses of the HLA peptidome of three CLL patient samples found only minor qualitative and quantitative effects of lenalidomide on HLA class I- and II-restricted peptide presentation. Furthermore, we confirmed stable presentation of previously described CLL-associated antigens under lenalidomide treatment. Strikingly, among the few HLA ligands showing significant modulation under lenalidomide treatment, we identified upregulated IKZF-derived peptides, which may represent a direct reflection of the cereblon-mediated effect of lenalidomide on CLL cells. Since we could not observe any relevant influence of lenalidomide on the established CLL-associated antigen targets of anticancer T-cell responses, this study validates the suitability of lenalidomide for the combination with antigen-specific T-cell-based immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. HLA ligandome tumor antigen discovery for personalized vaccine approach.
- Author
-
Rammensee, Hans-Georg and Singh-Jasuja, Harpreet
- Abstract
Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Self Tolerance of Natural MHC Class I Ligands.
- Author
-
Rammensee, Hans-Georg, Rötzschke, Olaf, and Falk, Kirsten
- Published
- 1993
- Full Text
- View/download PDF
7. Veto Function in Vitro and in Vivo.
- Author
-
Rammensee, Hans-Georg
- Published
- 1989
- Full Text
- View/download PDF
8. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.
- Author
-
Eckert, Franziska, Schaedle, Philipp, Zips, Daniel, Schmid-Horch, Barbara, Rammensee, Hans-Georg, Gani, Cihan, and Gouttefangeas, Cécile
- Subjects
PROSTATE cancer treatment ,CANCER radiotherapy ,IMMUNOTHERAPY - Abstract
Combination of radiotherapy with immunotherapy has become an attractive concept for the treatment of cancer. The objective of this study was to assess the effect of curative, normofractionated radiotherapy on peripheral immune lymphocytes in prostate cancer patients, in order to propose a rationale for scheduling of normofractionated radiotherapy with T-cell based immunotherapy. In a prospective study (clinicaltrials.gov: NCT01376674), eighteen patients with localized prostate cancer were treated with radiotherapy with or without hormonal therapy. Irradiation volumes encompassed prostate and, in select cases, elective pelvic nodal regions. Blood samples were collected from all patients before, during, and after radiotherapy, as well as from 6 healthy individuals as control. Normofractionated radiotherapy of prostate cancer over eight weeks had a significant influence on the systemic immune status of patients compared to healthy controls. Absolute leukocyte and lymphocyte counts decreased during treatment as did peripheral blood immune subsets (T cells, CD8
+ and naïve CD4+ T cells, B cells). Regulatory T cells and NK cells increased. Proliferation of all immune cells except regulatory T cells increased during RT. Most of these changes were transient. Importantly, the functionality of T lymphocytes and the frequency of antigen-specific CD8+ T cells were not affected during therapy. Our data indicate that combination of normofractionated radiotherapy with immunotherapy might be feasible for patients with prostate cancer. Conceptually, beginning with immunotherapy early during the course of radiotherapy could be beneficial, as the percentage of T cells is highest, the percentage of regulatory T cells is lowest, and as the effects of radiotherapy did not completely subside 3 months after end of radiotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
9. HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy.
- Author
-
Nelde, Annika, Walz, Juliane Sarah, Kowalewski, Daniel Johannes, Schuster, Heiko, Wolz, Olaf-Oliver, Peper, Janet Kerstin, Cardona Gloria, Yamel, Langerak, Anton W., Muggen, Alice F., Claus, Rainer, Bonzheim, Irina, Fend, Falko, Salih, Helmut Rainer, Kanz, Lothar, Rammensee, Hans-Georg, Stevanović, Stefan, and Weber, Alexander N. R.
- Subjects
HLA histocompatibility antigens ,LYMPHOMAS ,IMMUNOTHERAPY - Abstract
Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recurring somatic and oncogenic driver mutation of the Toll-like receptor adaptor proteinMYD88, Leu265Pro (L265P) was identified in up to 90% of different NHL subtype patients. We therefore screened the potential ofMYD88L265P-derived peptides to elicit cytotoxic T cell responses as tumor-specific neoantigens. Based onin silicopredictions, we identified potentialMYD88L265P-containing HLA ligands for several HLA class I restrictions. A set of HLA class IMYD88L265P-derived ligands elicited specific cytotoxic T cell responses for HLA-B*07 and -B*15. These data highlight the potential ofMYD88L265Pmutation-specific peptide-based immunotherapy as a novel personalized treatment approach for patients withMYD88L265P+NHLs that may complement pharmacological approaches targeting oncogenic MyD88 L265P signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.
- Author
-
Klatt, Martin G., Kowalewski, Daniel J., Schuster, Heiko, Di Marco, Moreno, Hennenlotter, Jörg, Stenzl, Arnulf, Rammensee, Hans-Georg, and Stevanović, Stefan
- Subjects
IMMUNOTHERAPY ,RENAL cell carcinoma ,IMMUNOPRECIPITATION ,HLA histocompatibility antigens ,T cells - Abstract
Despite recent advances in immunotherapy of renal cell carcinoma (RCC), peptide vaccination strategies still lack an approach for personalized peptide vaccination that takes intra- and inter-tumoral heterogeneity and biological characteristics into account. In this study, we use an immunoprecipitation and mass spectrometry-based approach supplemented by network analysis of HLA ligands to target this goal. By analyzing HLA-presented peptides for HLA class I and II of 11 malignant and 6 non-malignant kidney tissue samples, more than 2,700 peptides and 1,600 corresponding source proteins were identified. A high overlap with HLA ligands derived from peripheral blood mononuclear cells (PBMCs) was detected most likely due to tumor-infiltrating inflammatory cells and therefore excluded from network analysis. Subsequent biological function analysis of HLA ligands by the GeneMANIA online platform showed enrichment for well established, but also novel, pathways and biological processes involved in carcinogenesis of RCC almost exclusively in malignant tissue samples. By exploring source proteins involved in these overrepresented pathways, we verified various known tumor-associated antigens (TAAs) for RCC (e.g., CA9, EGLN3, IGFBP3, MMP7, PAX2, VEGFA, or EGFR) but could also detect novel TAAs for RCC (e.g., PLOD2, LOX, ENPEP, or TGFBI). Some of these new TAAs had already been shown to elicit a T cell response in cancer patients. Thus, network analysis of HLA ligands provided a new platform for implementing personalized, multipeptide vaccines with potentially synergistic antitumor effects. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
11. HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
- Author
-
Peper, Janet Kerstin, Bösmüller, Hans-Christian, Schuster, Heiko, Gückel, Brigitte, Hörzer, Helen, Roehle, Kevin, Schäfer, Richard, Wagner, Philipp, Rammensee, Hans-Georg, Stevanović, Stefan, Fend, Falko, and Staebler, Annette
- Subjects
HLA histocompatibility antigens ,OVARIAN cancer ,HISTONE deacetylase ,IMMUNOTHERAPY ,LIGANDS (Biochemistry) - Abstract
The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevant targets is enabled by analyzing the HLA ligandome of cancer cells. Since recent publications demonstrate the immunogenicity of ovarian cancer (OvCa), immunotherapies, including peptide-based cancer vaccines, represent a promising treatment approach. To identify vaccine peptides, we employed a combined strategy of HLA ligandomics in high-grade serous OvCa samples and immunogenicity analysis. Only few proteins were naturally presented as HLA ligands on all samples analyzed, including histone deacetylase (HDAC) 1 and 2.In vitropriming of CD8+T cells demonstrated that two HDAC1/2-derived HLA ligands can induce T-cell responses, capable of killing HLA-matched tumor cells. High HDAC1 expression shown by immunohistochemistry in 136 high-grade serous OvCa patients associated with significantly reduced overall survival (OS), whereas patients with high numbers of CD3+tumor-infiltrating lymphocytes (TILs) in the tumor epithelium and CD8+TILs in the tumor stroma showed improved OS. However, correlating HDAC1 expression with TILs, high levels of TILs abrogated the impact of HDAC1 on OS. This study strengthens the role of HDAC1/2 as an important tumor antigen in OvCa, demonstrating its impact on OS in a large cohort of OvCa patients. We further identified two immunogenic HDAC1-derived peptides, which frequently induce multi-functional T-cell responses in many donors, suitable for future multi-peptide vaccine trials in OvCa patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy.
- Author
-
Rittig, Susanne M., Haentschel, Maik, Weimer, Katrin J., Heine, Annkristin, Müller, Martin R., Brugger, Wolfram, Horger, Marius S., Maksimovic, Olga, Stenzl, Arnulf, Hoerr, Ingmar, Rammensee, Hans-Georg, Holderried, Tobias A., Kanz, Lothar, Pascolo, Steve, and Brossart, Peter
- Subjects
RENAL cell carcinoma ,RENAL cancer ,MESSENGER RNA ,IMMUNOLOGY ,IMMUNOTHERAPY - Abstract
Renal cell carcinoma (RCC) is an immunogenic tumor for which immunotherapeutic approaches could be associated with clinically relevant responses. It was recently shown, that induction of T-cell responses against multiple tumor-associated antigen (TAA) epitopes results in prolonged overall survival in RCC patients. In 2003–2005, we performed a phase I/II trial testing an mRNA-based vaccine formulation consisting of a mixture ofin vitrotranscribed RNA coding for six different TAAs (MUC1, CEA, Her2/neu, telomerase, survivin, MAGE-A1) in 30 metastatic RCC (mRCC) patients. In the first 14 patients, vaccinations were applied i.d. on days 0, 14, 28, and 42. In the consecutive 16 patients, an intensified protocol consisting of i.d. injections (daily on days 0–3, 7–10, 28, and 42) was used. After the respective induction periods, patients in both cohorts were vaccinated monthly until tumor progression. At survival update performed in July 2015, one of the 30 patients was still alive. One patient was lost to follow-up. Median survival of 24.5 mo (all patients) and 89 mo (favorable risk patients) exceeded predicted survival according to Memorial Sloan Kettering Cancer Center (MSKCC) risk score. Impressively, long-term survivors displayed immunological responses to the applied antigens while vice versa no patient without detectable immune response had survived more than 33 mo. The current survival update shows a clear correlation between survival and immunological responses to TAAs encoded by the naked mRNA vaccine. This is one of the first vaccination studies and the only RNA trial that reports on safety and efficacy after a follow-up of more than 10 y. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Antileukemia T-cell responses in CLL – We don't need no aberration.
- Author
-
Kowalewski, Daniel J, Stevanovic, Stefan, Rammensee, Hans-Georg, and Stickel, Juliane S
- Subjects
T cells ,CANCER immunotherapy ,LEUKEMIA immunology ,EPITOPES ,TUMOR antigens ,CANCER patients - Abstract
Effective antigen-specific cancer immunotherapy requires exact knowledge of tumor-associated epitopes that can act as rejection antigens. Although the current paradigm views mutation-derived neoantigens as the most promising targets, we have recently demonstrated that leukemia-specific T-cell responses associated with survival benefit in CLL patients target a panel of non-mutated tumor-associated antigens. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.